argenex SE (NASDAQ:ARGX) Receives Consensus Rating of “Buy” from Analysts

argenex SE (NASDAQ:ARGX) has received an average rating of “Buy” from the twenty-one research firms that are covering the company, MarketBeat.com reports. Nineteen research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $746.8125.

A number of equities research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, July 8th. JPMorgan Chase & Co. raised their target price on shares of argenex from $775.00 to $830.00 and gave the company an “overweight” rating in a research report on Monday. Oppenheimer boosted their target price on shares of argenex from $704.00 to $708.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Baird R W upgraded argenex from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 13th. Finally, Morgan Stanley boosted their price objective on argenex from $700.00 to $766.00 and gave the stock an “overweight” rating in a research report on Friday.

argenex Price Performance

NASDAQ ARGX opened at $690.32 on Tuesday. The business has a fifty day moving average price of $573.16 and a two-hundred day moving average price of $596.64. The stock has a market capitalization of $42.25 billion, a PE ratio of 35.40, a PEG ratio of 0.93 and a beta of 0.39. argenex has a fifty-two week low of $475.65 and a fifty-two week high of $691.02.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%. The business had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. As a group, sell-side analysts expect that argenex will post 3.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Moody Aldrich Partners LLC acquired a new stake in shares of argenex during the second quarter worth $479,000. Atria Investments Inc boosted its position in argenex by 3.4% during the second quarter. Atria Investments Inc now owns 2,708 shares of the company’s stock valued at $1,493,000 after acquiring an additional 90 shares during the last quarter. Assetmark Inc. grew its holdings in argenex by 1.1% during the 2nd quarter. Assetmark Inc. now owns 9,027 shares of the company’s stock worth $4,976,000 after acquiring an additional 101 shares during the period. Hantz Financial Services Inc. raised its position in shares of argenex by 25.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 695 shares of the company’s stock worth $383,000 after acquiring an additional 141 shares in the last quarter. Finally, Wealth Management Associates Inc. lifted its stake in shares of argenex by 19.0% in the 2nd quarter. Wealth Management Associates Inc. now owns 539 shares of the company’s stock valued at $297,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.